Esketamine and Perioperative Depressive Symptoms

This parallel, randomised, quadruple-masked trial evaluates the efficacy and safety of a single intra-operative intravenous esketamine infusion (0.2 mg/kg over 40 minutes) administered during wound closure for moderate to severe perioperative depressive symptoms in adults undergoing major elective surgery.

Secondary outcomes include anxiety, postoperative pain and broader psychiatric and safety assessments. Actual enrolled count of 435 is reported on the registry.